FDA Regulatory Relaxations Due to COVID-19

Over recent months, the U.S. Food and Drug Administration (FDA) has relaxed regulations in several areas to keep up with the COVID-19 pandemic. Regulatory relaxations have been made to address interruptions in the supply chain, expedite clinical trials and product reviews, and increase the accessibility of both diagnostic tests and treatments.